Doximity (DOCS) Stock Forecast & Price Target

Doximity is supported by a strong fundamental backdrop, as fiscal Q1 revenue of about $156.6M to $157M grew roughly 7% year over year and beat expectations, adjusted EBITDA reached about $74.8M to $75M with a 47.7% to 48% margin, net revenue retention held at 107% overall and 112% among top customers, and the balance sheet remained pristine with $688M of cash and no debt. The company’s outlook is further strengthened by early traction in AI Search, which management says is expanding customer engagement, opening a new budget category with pharmaceutical customers, and improving the performance of legacy products through better physician insights and relevance, while workflow active prescribers reached about 800k, up 30% year over year, and roughly 50% of users are now engaging with AI tools. Although AI investment and compute costs are pressuring near-term margins and FY27 EBITDA guidance has been lowered to fund product innovation, the company’s conservative revenue guide, evidence of stabilizing pharma budgets, strong free cash flow conversion, and durable platform leadership suggest the revenue opportunity from AI and the core network can outweigh the temporary margin drag over time.

Doximity is facing a weaker fundamental setup as constrained pharma budgets, MFN-related spending delays, and a digital pharma advertising market growing at or below 5% point to only about 5% top-line growth in FY27, making a meaningful revenue surprise unlikely without a sharp budget recovery or materially stronger AI search adoption. Its growth visibility is further limited by short-cycle contracts—generally 12 months or less across Marketing, Hiring, and Workflow Solutions—so renewals and mix shifts can quickly pressure revenue if customers buy fewer modules or accept less favorable terms, while regulatory limits around PHI also constrain data-rich advertising product expansion. Although AI Search and AI Scribe are early positives, the company faces intensifying competition from OpenEvidence, Abridge, Nabla, and Epic’s AI Charting, and the risk that customers shift toward integrated alternatives means Doximity may be moving into a more mature, lower-visibility growth phase despite still attractive EBITDA margins.